Treatment
Tki clinical trials
We’re tracking 58 recruiting studies that include Tki, each written for real people, not researchers, below.
Recruiting studies
- NCT07479485RecruitingPhase 1/Phase 2
MRG006A combo for advanced liver cancer
This trial tests a new drug combination called MRG006A for people with advanced liver cancer (hepatocellular carcinoma) that cannot be removed by surgery or treated with local therapies. The goal is to see if it helps shrink tumors or slow cancer growth.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06765109RecruitingPhase 3
Testing neladalkib for untreated ALK-positive lung cancer
This study tests a new pill called neladalkib to see if it works better than the current standard treatment (alectinib) for people with ALK-positive lung cancer who have not yet received any cancer therapy for advanced disease. It may be a good option if you have ALK-positive NSCLC and have not been treated before.
Glendale, ArizonaAges 18 years+ - NCT07091019Recruiting
CML patient experience study on standard TKI therapy
This study tracks the experiences and health outcomes of people with chronic myeloid leukemia (CML) who are taking approved first or second line tyrosine kinase inhibitor (TKI) medicines. It helps doctors learn how these treatments work in everyday care.
Birmingham, AlabamaAges 18–100 - NCT04777994RecruitingPhase 1
Drug ABBV-CLS-484 for advanced cancers that lack options
This Phase 1 trial tests ABBV-CLS-484 in people with advanced or metastatic tumors when standard treatments have not worked or aren’t available. Because it’s an early study, the main goal is to find a safe dose and see how the cancer responds in different cancer types.
Tucson, ArizonaAges 18 years+ - NCT04835584RecruitingPhase 1/Phase 2
Testing KRT-232 with a TKI for CML that didn’t respond
This trial studies a new drug (KRT-232) combined with a standard CML “TKI” medicine to treat chronic myeloid leukemia (CML) that is resistant or not tolerated after at least one prior TKI. It may help people whose leukemia hasn’t controlled as expected on current treatments.
Birmingham, AlabamaAges 18 years+ - NCT04838041RecruitingPhase 2
Testing stopping treatment after asciminib for CML relapse
This trial looks at whether people with chronic-phase CML who tried stopping a prior CML medicine and had to restart can later stop treatment again after a set period using asciminib. It checks whether you can stay in a deep remission (“free remission” without the usual CML tablets).
Detroit, MichiganAges 18 years+ - NCT05221372Recruiting
Sampling study for lung cancer patients on targeted pills
This trial collects blood samples from adults with advanced lung cancer that has a specific gene change and who are already taking targeted pill treatment (TKIs). The goal is to learn from these samples and how they relate to the cancer in patients on standard therapy.
RotterdamAges 18 years+ - NCT05598528Recruiting
Study why some lung cancers don’t respond to EGFR pills
This study looks at why certain EGFR-positive advanced lung cancers resist third-generation EGFR tablet treatment given as the first treatment. Your body samples and scan results help researchers understand the resistance, which may guide better future care.
Changsha, HunanAges 18 years+ - NCT05620771RecruitingPhase 2
Y-90 radioembolization plus treatment for high-risk liver cancer
This Phase 2 trial tests TheraSphere® (a Y-90 radiation treatment delivered to the liver) combined with standard systemic therapy in people with high-risk hepatocellular carcinoma (HCC). It aims to shrink tumors and improve outcomes for people whose liver cancer is at higher risk to worsen.
Chicago, IllinoisAges 18 years+ - NCT05682924Recruiting
Study blood vessel function in CML patients on bosutinib
This study looks at how well your blood vessels work (“vasoregulation”) in people with chronic myeloid leukemia (CML) while taking bosutinib. The goal is to understand vascular changes and how they relate to treatment in CML.
MoscowAges 40–60 - NCT05751733Recruiting
Apatinib versus standard drug for advanced GIST after imatinib
This trial studies whether apatinib works better than the usual second-line targeted tablet for advanced gastrointestinal stromal tumor (GIST) after imatinib (or avatinib) no longer works. It may help people whose cancer has grown despite treatment or who couldn’t tolerate it.
Changsha, HunanAges 18 years+ - NCT05852990RecruitingPhase 3
Gut help to prevent diarrhea from EGFR-targeted lung cancer drugs
This Phase 3 trial tests whether adding glutamine plus L. reuteri can help prevent severe diarrhea caused by EGFR-targeted treatments in people with advanced non-small cell lung cancer. If it works, it could make treatment easier to tolerate and help you stay on the planned therapy.
Mexico City, Mexico CityAges 18–80 - NCT06051409RecruitingPhase 3
Olverembatinib for newly diagnosed Ph+ ALL
This trial tests a new targeted drug, olverembatinib, in adults newly diagnosed with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The goal is to see if this drug can help control the leukemia with manageable side effects.
Birmingham, AlabamaAges 18 years+ - NCT06145308RecruitingPhase 2
Precision treatment for salivary gland cancer
This trial tests a personalized treatment approach for recurrent or metastatic salivary gland cancer. It uses special tests on your tumor to find the best targeted therapy for your specific cancer type.
Beijing, Beijing MunicipalityAges 18–100 - NCT06167460Recruiting
Blood test to monitor targeted therapy response in advanced lung cancer
This study uses a simple blood test to look at bits of tumor DNA (called circulating tumor DNA) to see how well your targeted therapy (TKI) is working. It helps doctors predict and monitor whether the treatment is effective for your advanced lung cancer.
Ho Chi Minh CityAges 18–80 - NCT06195189RecruitingPhase 1/Phase 2
Sunvozertinib Plus Chemo for EGFR Lung Cancer After TKI Failure
This trial tests a new pill (sunvozertinib) combined with chemotherapy for people with a specific EGFR mutation type of lung cancer whose previous targeted pill stopped working. It aims to see if the combination can shrink tumors or slow the cancer's growth.
Chengdu, SichuanAges 18–80 - NCT06343064RecruitingPhase 1/Phase 2
Vebreltinib plus PLB1004 for EGFR-mutant lung cancer with MET changes
This trial tests a combination of two targeted drugs (Vebreltinib and PLB1004) for people with advanced non-small cell lung cancer that has a specific EGFR mutation and has developed MET amplification or overexpression after previous EGFR-targeted therapy. The goal is to see if this combination can help shrink tumors or slow their growth.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06481228Recruiting
TKI plus chemo and CAR-T for newly diagnosed Ph+ ALL
This trial tests combining a targeted drug (TKI) with chemotherapy and then CAR-T cells for adults who are newly diagnosed with Philadelphia chromosome-positive ALL. The goal is to see if this combination is safe and effective.
TianjinAges 18 years+ - NCT06543836RecruitingPhase 2
Targeted therapy plus immunotherapy for advanced colorectal cancer
This trial tests a combination of a targeted therapy pill (TKI) and an immunotherapy (PD-1 inhibitor) for people with advanced colorectal cancer that has stopped responding to standard treatments. It uses a blood test to tailor the treatment, aiming to be more effective with fewer side effects.
Beijing, Beijing MunicipalityAges 18–80 - NCT06604689Recruiting
AI-guided brain radiation for EGFR-mutant lung cancer with brain mets
This study uses AI to help doctors decide the best way to use brain radiation for people with EGFR-mutant lung cancer that has spread to the brain. It aims to improve treatment planning and outcomes for those already taking a third-generation targeted therapy.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06652048RecruitingPhase 2
High-dose Furmonertinib for advanced lung cancer after progression
This trial tests a higher dose of the targeted therapy Furmonertinib, either alone or with chemotherapy, for people with advanced non-small cell lung cancer that has progressed after initial treatment with a third-generation EGFR inhibitor like Osimertinib or Almonertinib.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT02889003RecruitingPhase 2
Second attempt to stop treatment after pioglitazone in CML
This trial tests if a short course of pioglitazone (a diabetes drug) before stopping your TKI therapy can help you stay in remission longer. It is for people with chronic myeloid leukemia (CML) who have already lost their remission after a first or later attempt to stop TKI treatment.
Le ChesnayAges 18 years+ - NCT06718257Recruiting
Chemo with immunotherapy and targeted drugs for bile duct cancer
This trial tests whether adding immunotherapy and targeted therapy to standard chemotherapy can help treat intrahepatic cholangiocarcinoma (a type of bile duct cancer). It is for patients who are starting treatment with one of two specific chemo regimens, possibly combined with the new drugs.
Hangzhou, ZhejiangAges 18 years+ - NCT06830694RecruitingPhase 2
Trial of a new drug combo for a rare type of lung cancer
This trial tests a new drug (tarlatamab) combined with chemotherapy and immunotherapy for people whose lung cancer has changed from one type (adenocarcinoma) to small cell lung cancer after treatment with EGFR targeted therapy. The goal is to see if this combination is safe and works well.
Seoul, Gangnam-guAges 19 years+
Common questions
- Are there clinical trials studying Tki?
- Yes. Clin2 currently lists 58 recruiting studies that include Tki, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Tki trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Tki an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Tki or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.